Adaptimmune Therapeutics PLC
NASDAQ:ADAP
Adaptimmune Therapeutics PLC
Pre-Tax Income
Adaptimmune Therapeutics PLC
Pre-Tax Income Peer Comparison
Competitive Pre-Tax Income Analysis
Latest Figures & CAGR of Competitors
Company | Pre-Tax Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Adaptimmune Therapeutics PLC
NASDAQ:ADAP
|
Pre-Tax Income
-$112.5m
|
CAGR 3-Years
5%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
N/A
|
|
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
|
Pre-Tax Income
-$176.1m
|
CAGR 3-Years
-155%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Autolus Therapeutics PLC
NASDAQ:AUTL
|
Pre-Tax Income
-$208.4m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
Pre-Tax Income
-$166.4m
|
CAGR 3-Years
-43%
|
CAGR 5-Years
-45%
|
CAGR 10-Years
N/A
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Pre-Tax Income
-£60.9m
|
CAGR 3-Years
11%
|
CAGR 5-Years
7%
|
CAGR 10-Years
N/A
|
|
Genus PLC
LSE:GNS
|
Pre-Tax Income
£38.7m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
2%
|
See Also
What is Adaptimmune Therapeutics PLC's Pre-Tax Income?
Pre-Tax Income
-112.5m
USD
Based on the financial report for Dec 31, 2023, Adaptimmune Therapeutics PLC's Pre-Tax Income amounts to -112.5m USD.
What is Adaptimmune Therapeutics PLC's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 5Y
-3%
Over the last year, the Pre-Tax Income growth was 31%. The average annual Pre-Tax Income growth rates for Adaptimmune Therapeutics PLC have been 5% over the past three years , -3% over the past five years .